Clinical trial

A Real-world Study Comparing the Effectiveness of Ofatumumab and Ocrelizumab Treatment in Multiple Sclerosis Patients

Novartis PharmaceuticalsCompletedStarted Oct 25, 20242604 enrolledUnited StatesNCT07566988

Abstract

The aim of this study was to compare the effectiveness and economic burden of ofatumumab (OMB) and ocrelizumab (OCR) treatment in multiple sclerosis (MS) patients in the United States using data from an administrative claims database.

Keywords

Multiple sclerosisAnti-CD20 monoclonal antibodyOfatumumabOcrelizumabReal-world evidenceComparative effectivenessAnnualized relapse rateHealthcare resource utilizationMultiple Sclerosis

View on registry

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.